Evidence map›Paper›PMID 28480080›Full record

ArticleJournal of drug delivery2017

Deformable Nanovesicles Synthesized through an Adaptable Microfluidic Platform for Enhanced Localized Transdermal Drug Delivery.

Naren Subbiah, Jesus Campagna, Patricia Spilman, Mohammad Parvez Alam, Shivani Sharma, Akishige Hokugo, Ichiro Nishimura, Varghese John

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of drug delivery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Naren SubbiahDrug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, USA.
Jesus CampagnaDrug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, USA.
Patricia SpilmanDrug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, USA.
Mohammad Parvez AlamDrug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, USA.
Shivani SharmaCalifornia NanoSystems Institute, University of California, Los Angeles, CA, USA.
Akishige HokugoRegenerative Bioengineering and Repair Laboratory, Department of Surgery, University of California, Los Angeles, CA, USA.
Ichiro NishimuraWeintraub Center for Reconstructive Biotechnology, School of Dentistry, University of California, Los Angeles, CA, USA.
Varghese JohnDrug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, USA.ORCID 0000-0001-7675-2426

Funding

Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJR44DE025524 · NIDCR · BIOVINC, LLC · PI EBETINO, FRANK H. · 2017 to 2018
$2.2M
Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJR43DE025524 · NIDCR · BIOVINC, LLC · PI EBETINO, FRANK H., NISHIMURA, ICHIRO · 2015 to 2015
$150k
NIDCR NIH HHS R43 DE025524NIDCR NIH HHS R44 DE025524
6 · The paper itself

Abstract

Phospholipid-based deformable nanovesicles (DNVs) that have flexibility in shape offer an adaptable and facile method to encapsulate diverse classes of therapeutics and facilitate localized transdermal delivery while minimizing systemic exposure. Here we report the use of a microfluidic reactor for the synthesis of DNVs and show that alteration of input parameters such as flow speeds as well as molar and flow rate ratios increases entrapment efficiency of drugs and allows fine-tuning of DNV size, elasticity, and surface charge. To determine the ability of DNV-encapsulated drug to be delivered transdermally to a local site, we synthesized, characterized, and tested DNVs carrying the fluorescently labeled hydrophilic bisphosphonate drug AF-647 zoledronate (AF647-Zol). AF647-Zol DNVs were lyophilized, resuspended, and applied topically as a paste to the calvarial skin of mice. High-resolution fluorescent imaging and confocal microscopy revealed significant increase of encapsulated payload delivery to the target tissue-cranial bone-by DNVs as compared to nondeformable nanovesicles (NVs) or aqueous drug solutions. Interestingly, NV delivery was not superior to aqueous drug solution. Our studies show that microfluidic reactor-synthesized DNVs can be produced in good yield, with high encapsulation efficiency, reproducibility, and stability after storage, and represent a useful vehicle for localized transdermal drug delivery.

Identifiers

PMID28480080
PMCPMC5396447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.